Bioceres (BIOX) Q3 2026 Earnings Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIOX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIOX
Wall Street analysts forecast BIOX stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 0.395
Low
2.00
Averages
2.00
High
2.00
Current: 0.395
Low
2.00
Averages
2.00
High
2.00
About BIOX
Bioceres Crop Solutions Corp. is a provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. Its segments include Seed and integrated products, Crop protection and Crop nutrition. Seed and integrated products segment focuses on the development and commercialization of seed technologies and products, including provision of seed technologies integrated with crop protection and crop nutrition products designed to control weeds, insects or diseases, to increase their quality characteristics. Crop protection segment includes the development, production and marketing of adjuvants and a range of pest control molecules and biocontrol products. Crop nutrition segment focuses on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops, and of fertilizers, including biofertilizers and micro-granulated fertilizers that optimize the productivity and yield of the crops.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bioceres (BIOX) Q3 2026 Earnings Transcript
See More
Bioceres (BIOX) Q1 2026 Earnings Transcript
See More
Bioceres Crop Solutions Earnings Call Insights
- Revenue Decline: Bioceres Crop Solutions reported a 23% year-over-year decline in total revenue, primarily due to softer market conditions and ongoing portfolio transitions, which places financial pressure on the company and impacts future growth potential.
- Significant Gross Profit Drop: The company's gross profit fell by 30% year-over-year, with broad declines across all segments, indicating severe challenges to profitability in the current market environment, necessitating measures to improve financial health.
- Growth in Crop Nutrition: Despite the overall revenue decline, the crop nutrition segment achieved a 15% year-over-year growth, driven by increased demand for microbeaded fertilizers, suggesting that this area still holds growth potential and could become a future business highlight.
- Litigation Risks: The company is facing ongoing litigation related to the ProFarm Group, involving a non-cash impairment loss of approximately $179 million, which adds financial uncertainty and could affect investor confidence and stock performance.
See More
Bioceres Crop Solutions Reports Q3 Fiscal 2026 Earnings Decline Amid Transition
- Declining Financial Performance: Bioceres Crop Solutions reported total revenues of $39.4 million for Q3, reflecting a 23% year-over-year decline primarily due to an 18% drop in Crop Protection revenue to $24.6 million, while Seeds and Integrated Products revenue plummeted 71%, indicating significant competitive pressures in the market.
- Gross Margin Contraction: The gross profit for the quarter was $12.7 million, down from $18.1 million last year, with gross margin decreasing from 35% to 32%, highlighting challenges in cost control and the impact of product mix effects and nonrecurring adjustments on profitability.
- Increased Liquidity Risk: As of March 31, 2026, the company reported total financial debt of approximately $229 million, with cash and short-term investments totaling only $14 million, resulting in a net financial debt of about $214 million, underscoring urgent liquidity management concerns.
- Litigation Risk: The company faces heightened litigation risks as four holders of secured notes filed a lawsuit in New York, and while the company strongly disputes these allegations, the case remains in its early stages, potentially impacting future financial stability.
See More
Bioceres Reports Q3 Loss Amid Revenue Decline
- Poor Financial Performance: Bioceres reported a net loss of $10 million in Q3, with an adjusted EBITDA of negative $0.6 million, indicating significant challenges in profitability.
- Significant Revenue Decline: The company's revenue of $39.4 million represents a 22.9% year-over-year decrease, missing expectations by $15.1 million, reflecting weak market demand and increased competition.
- Market Reaction: Despite Bioceres' disappointing results, fertilizer stocks rallied due to supply fears in the Middle East, indicating heightened market interest and investor sentiment volatility.
- Uncertain Future Outlook: Given the current economic environment, Bioceres' financial performance may impact its future investment and expansion plans, necessitating close monitoring of the company's strategic adjustments and market responses.
See More
Bioceres Reports Q2 Financial Results Amid Challenges
- Financial Performance Pressure: Bioceres' Q2 financial results reveal revenue and working capital impacts due to sustained pressure on Argentine farmer economics, although the consolidated gross margin across its three business segments remains at 40%, demonstrating the resilience of its technology-driven product portfolio.
- Asset Disposal and Impairment: A foreclosure auction for Pro Farm assets occurred on January 20, 2026, with a bid of $15 million against a carrying value of approximately $194 million, resulting in a $179 million impairment loss, highlighting significant financial challenges faced by the company.
- Financing and Capital Structure: The company continues to face substantial doubt regarding its ability to secure additional financing, actively engaging with local Argentine financial institutions to refinance obligations while evaluating asset disposals and long-term financing options to restore market confidence and improve capital structure.
- Board Governance Strengthening: Bioceres has strengthened its board by adding two new non-executive directors in Q2 of fiscal 2026, focusing on enhancing governance and independent oversight to navigate current challenges and ensure transparency with shareholders.
See More
Bioceres (BIOX) Q3 2026 Earnings Transcript
See More
Bioceres (BIOX) Q1 2026 Earnings Transcript
See More
Bioceres Crop Solutions Earnings Call Insights
- Revenue Decline: Bioceres Crop Solutions reported a 23% year-over-year decline in total revenue, primarily due to softer market conditions and ongoing portfolio transitions, which places financial pressure on the company and impacts future growth potential.
- Significant Gross Profit Drop: The company's gross profit fell by 30% year-over-year, with broad declines across all segments, indicating severe challenges to profitability in the current market environment, necessitating measures to improve financial health.
- Growth in Crop Nutrition: Despite the overall revenue decline, the crop nutrition segment achieved a 15% year-over-year growth, driven by increased demand for microbeaded fertilizers, suggesting that this area still holds growth potential and could become a future business highlight.
- Litigation Risks: The company is facing ongoing litigation related to the ProFarm Group, involving a non-cash impairment loss of approximately $179 million, which adds financial uncertainty and could affect investor confidence and stock performance.
See More
Bioceres Crop Solutions Reports Q3 Fiscal 2026 Earnings Decline Amid Transition
- Declining Financial Performance: Bioceres Crop Solutions reported total revenues of $39.4 million for Q3, reflecting a 23% year-over-year decline primarily due to an 18% drop in Crop Protection revenue to $24.6 million, while Seeds and Integrated Products revenue plummeted 71%, indicating significant competitive pressures in the market.
- Gross Margin Contraction: The gross profit for the quarter was $12.7 million, down from $18.1 million last year, with gross margin decreasing from 35% to 32%, highlighting challenges in cost control and the impact of product mix effects and nonrecurring adjustments on profitability.
- Increased Liquidity Risk: As of March 31, 2026, the company reported total financial debt of approximately $229 million, with cash and short-term investments totaling only $14 million, resulting in a net financial debt of about $214 million, underscoring urgent liquidity management concerns.
- Litigation Risk: The company faces heightened litigation risks as four holders of secured notes filed a lawsuit in New York, and while the company strongly disputes these allegations, the case remains in its early stages, potentially impacting future financial stability.
See More
Bioceres Reports Q3 Loss Amid Revenue Decline
- Poor Financial Performance: Bioceres reported a net loss of $10 million in Q3, with an adjusted EBITDA of negative $0.6 million, indicating significant challenges in profitability.
- Significant Revenue Decline: The company's revenue of $39.4 million represents a 22.9% year-over-year decrease, missing expectations by $15.1 million, reflecting weak market demand and increased competition.
- Market Reaction: Despite Bioceres' disappointing results, fertilizer stocks rallied due to supply fears in the Middle East, indicating heightened market interest and investor sentiment volatility.
- Uncertain Future Outlook: Given the current economic environment, Bioceres' financial performance may impact its future investment and expansion plans, necessitating close monitoring of the company's strategic adjustments and market responses.
See More
Bioceres Reports Q2 Financial Results Amid Challenges
- Financial Performance Pressure: Bioceres' Q2 financial results reveal revenue and working capital impacts due to sustained pressure on Argentine farmer economics, although the consolidated gross margin across its three business segments remains at 40%, demonstrating the resilience of its technology-driven product portfolio.
- Asset Disposal and Impairment: A foreclosure auction for Pro Farm assets occurred on January 20, 2026, with a bid of $15 million against a carrying value of approximately $194 million, resulting in a $179 million impairment loss, highlighting significant financial challenges faced by the company.
- Financing and Capital Structure: The company continues to face substantial doubt regarding its ability to secure additional financing, actively engaging with local Argentine financial institutions to refinance obligations while evaluating asset disposals and long-term financing options to restore market confidence and improve capital structure.
- Board Governance Strengthening: Bioceres has strengthened its board by adding two new non-executive directors in Q2 of fiscal 2026, focusing on enhancing governance and independent oversight to navigate current challenges and ensure transparency with shareholders.
See More
